250 related articles for article (PubMed ID: 29753381)
21. Severe Hypocalcemia Following a Single Denosumab Injection.
Cernes R; Barnea Z; Biro A; Zandman-Goddard G; Katzir Z
Isr Med Assoc J; 2017 Nov; 19(11):719-721. PubMed ID: 29185289
[No Abstract] [Full Text] [Related]
22. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
Yerram P; Kansagra S; Abdelghany O
J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
[TBL] [Abstract][Full Text] [Related]
23. Hypocalcaemia after denosumab in older people following fracture.
Chen J; Smerdely P
Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
[TBL] [Abstract][Full Text] [Related]
24. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
25. [Pharmaceutical Intervention According to Strict Management System Can Normalize Decreased Serum Calcium Level by Denosumab and Prevent Its Aggravation].
Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
Yakugaku Zasshi; 2021; 141(8):1023-1030. PubMed ID: 34334547
[TBL] [Abstract][Full Text] [Related]
26. Hypocalcemia in a Patient with Cancer.
Rosner MH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):696-699. PubMed ID: 28274993
[No Abstract] [Full Text] [Related]
27. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
28. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
29. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
30. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
Kostine M; Mehsen-Cetre N; Bannwarth B
Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
[No Abstract] [Full Text] [Related]
31. Case report: Recurrent severe hypocalcemia secondary to denosumab in a patient with chronic kidney disease.
Correia M; Pereira P; Ferreira CC; Cerqueira M; Almeida DE
Int J Rheum Dis; 2024 Jun; 27(6):e15211. PubMed ID: 38831530
[No Abstract] [Full Text] [Related]
32. Severe hypocalcemia following denosumab injection in patient with chronic kidney disease.
Monge Rafael P; Arias M; Fernández-Fresnedo G
Nefrologia; 2016; 36(4):446-8. PubMed ID: 27012438
[No Abstract] [Full Text] [Related]
33. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.
Tovazzi V; Dalla Volta A; Pedersini R; Amoroso V; Berruti A
Future Oncol; 2019 Jul; 15(20):2319-2321. PubMed ID: 31237145
[No Abstract] [Full Text] [Related]
34. Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.
Saleem S; Patel S; Ahmed A; Saleem N
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848528
[TBL] [Abstract][Full Text] [Related]
35. Extreme hypocalcaemia and hyperparathyroidism following denosumab. Is this drug safe in chronic kidney disease?
Sirvent AE; Enríquez R; Sánchez M; González C; Millán I; Amorós F
Nefrologia; 2014; 34(4):542-4. PubMed ID: 25036077
[No Abstract] [Full Text] [Related]
36. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
37. Denosumab-related hypocalcaemia in chronic kidney disease.
Yong CH
Aust J Gen Pract; 2018 Aug; 47(8):538-539. PubMed ID: 30114884
[No Abstract] [Full Text] [Related]
38. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.
Watkins KR; Rogers JE; Atkinson B
Support Care Cancer; 2015 Jun; 23(6):1657-62. PubMed ID: 25421444
[TBL] [Abstract][Full Text] [Related]
39. Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.
Shafqat H; Alquadan KF; Olszewski AJ
Osteoporos Int; 2014 Mar; 25(3):1187-90. PubMed ID: 24158473
[TBL] [Abstract][Full Text] [Related]
40. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
